It is, however, important to note that fibroblast activating protein (Fap) which has been found to inactivate FGF21 (178) is increased in NASH patients (179) and future studies are needed to distinguish between total and active plasma FGF21 in NASH. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.